The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

December 7, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2020—2020 is a year that will not soon be forgotten—for many reasons. But even amidst a pandemic, notable advances in clinical rheumatology are a silver lining for the year. During the ACR Convergence 2020 Clinical Year in Review session, Jinoos Yazdany, MD, MPH, Alice Betts Endowed Professor and chief of rheumatology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, discussed the highlights of these past 12 months and the ways in which numerous studies and discoveries will shape treatment changes in years to come.

You Might Also Like
  • The 2020 ACR Review Course: Key Issues Rheumatologists Face
  • Back to Basics: The 2020 Basic Science Year in Review
  • 2020 Pediatric Rheumatology Research in Review
Also By This Author
  • Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Dr. Yazdany

TULIP-2 Results
With regard to systemic lupus erythematosus, Dr. Yazdany discussed a phase 3, randomized, controlled trial of anifrolumab, a human monoclonal antibody to type 1 interferon receptor, published this year.1 As readers may recall, a prior study involving anifrolumab (the Treatment of Uncontrolled Lupus via the Interferon pathway [TULIP] 1 study) did not show a significant effect on the primary end point of the Systemic Lupus Erythematosus Responder Index (SRI) 4, which is a composite of changes in three scales.2 This was disappointing because a phase 2 trial of this medication had shown promising results.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, in the TULIP 2 study, the authors used the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) as the primary endpoint to evaluate more than 360 patients with moderate or severe active lupus. Patients were randomized to receive anifrolumab or placebo, and those with severe renal or central nervous system involvement were excluded from the study. Whereas SRI-4 requires complete resolution within a particular item to register change and, therefore, does not capture partial improvements, the BICLA can register partial and complete improvement within an organ system, noted the authors.

The TULIP 2 study showed 48% of patients who received a monthly administration of anifrolumab had a BICLA response, compared with 31.5% in the placebo group.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Yazdany said these studies indicate that trial endpoints of lupus studies can make a big difference, and it remains challenging to identify which endpoints to use. Also, large trials with years of endpoint scrutiny and planning are needed to identify the optimal treatments for lupus patients.

Practically speaking, the TULIP trials also indicate that—if approved by the U.S. Food & Drug Administration—anifrolumab may become a treatment option for patients with active lupus who do not have severe renal or central nervous system disease.

Tapering Glucocorticoids
Next, Dr. Yazdany discussed the theme of optimizing glucocorticoid dosing and safety in the treatment of rheumatologic diseases.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, anifrolumab, axial spondyloarthritis (SpA), Clinical research, COVID-19, Glucocorticoids, Lupus, rituximab, Vasculitis

You Might Also Like:
  • The 2020 ACR Review Course: Key Issues Rheumatologists Face
  • Back to Basics: The 2020 Basic Science Year in Review
  • 2020 Pediatric Rheumatology Research in Review
  • Jinoos Yazdany, MD, MPH, Advances RISE Through the Registries and Health IT Committee

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)